clinical trial · NCT06715124

QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations

Quanta Therapeutics Inc →·phase1·active not recruiting·n = 237

Advanced Solid TumorsQTX3544Cetuximab

brief summary

Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.

started

Jan 14, 2025

primary completion

Jan 2, 2027

completion

Jan 2, 2029

last updated

Mar 2, 2026

official title

A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol